Objective To investigate pregnant women's level of future interest in noninvasive prenatal diagnosis (NIPD) and what factors might affect expected uptake of this testing.
INTRODUCTION
The option of prenatal diagnostic testing for chromosome abnormalities has become a routine aspect of obstetric care, but the risk of miscarriage associated with currently available forms of diagnostic testing leads to relatively low uptake (Nakata et al., 2010) . The American Congress of Obstetricians and Gynecologists recommends that all pregnant women be offered both noninvasive screening and invasive diagnostic testing (Practice Bulletin #88). Diagnostic tests appear to be undertaken primarily by women for whom the numeric risk of aneuploidy is high (because of age or screening results) or who have high levels of anxiety (Mueller et al., 2005; Kobleka et al., 2009) , and many women at numerically higher risks decline diagnostic testing because of their concerns about the risks of an invasive test.
A noninvasive method of obtaining diagnostic information about the genetic make-up of the fetus has long been sought (Evans and Kilpatrick, 2010) . Noninvasive prenatal diagnosis (NIPD) would allow fetal genetic testing through a sample of the mother's blood. The isolation of fetal cells (Herzenberg et al., 1979) and later fetal cell-free DNA and RNA (Lo et al., 1997; Poon et al., 2000) circulating in the maternal bloodstream has made this type of testing a possibility. Ideally, NIPD would have no risk of miscarriage and could be available starting at an earlier point than current forms of diagnostic testing (De Jong et al., 2010; Hall et al., 2010) . Earlier diagnostic testing could allow for termination of affected pregnancies (if desired by the parents) when the procedure is physically safer and less psychologically traumatic (Benn and Chapman, 2010) and might allow for earlier reassurance and bonding in normal pregnancies (Newson, 2008) . Women historically prefer earlier prenatal tests (Spencer and Aitken, 2004) , although there is some evidence that healthcare providers may place a higher value on earlier tests than women do (Bishop et al., 2004) .
The development of noninvasive forms of fetal genetic testing has been an active area of research for many years. Recent progress in cell-free fetal DNA sequencing approaches are promising (Fan et al., 2008; Fan and Quake, 2010) . Several companies (including Verinata, Gene Security Network, and Sequenom) are trying to develop this technology (Verinata, 2011; Sequenom, 2011 , GSN, 2011 . Two large-scale validation studies published earlier this year indicate that this technology is approaching diagnostic specifications for the detection of fetal aneuploidy (Chiu et al., 2011; Ehrich et al., 2011) and widespread implementation of this technology is a realistic possibility within the next decade.
The broad implementation of NIPD would likely cause significant increase in the uptake of prenatal diagnostic testing because of the removal of miscarriage risk. This potential increase in uptake of diagnostic testing would lead to a larger number of affected pregnancies being identified, and terminations of affected pregnancies would almost certainly rise (Newson, 2008; Benn and Chapman, 2009 ). This raises concerns that if fewer affected individuals are born, this might eventually lead to less social support and acceptance of people with disabilities (Skotko, 2009; Greely, 2011) . In a circular manner, decreased social acceptance of individuals with disabilities could cause pregnant women to feel undue pressure to undergo NIPD testing and terminate an affected pregnancy. In fact, a 2001 study on NIPD using fetal cells showed that nearly a third of women imagined that they would feel pressure from society, their provider, or their partner to undergo a hypothetical noninvasive diagnostic test (Zamerowski et al., 2001) .
The risk of miscarriage associated with amniocentesis or chorionic villus sampling (CVS) and the invasive nature of these tests prompts healthcare professionals to have an in-depth discussion of the pros and cons of prenatal testing with their patients. For the pregnant woman, the miscarriage risk and the need to undergo a separate invasive procedure act as psychological barriers that generally prompt her to carefully consider whether she values the information provided by a prenatal diagnostic test. When these barriers are removed, a woman may give less thoughtful consideration to her choice about diagnostic testing (Schmitz et al., 2009) , and healthcare professionals may provide less information about the potential ramifications of this type of testing (Van den Heuvel et al., 2009; Benn and Chapman, 2010) . When the risk of miscarriage is removed, a woman who does not want the information provided by a diagnostic test may also feel less justified in her decision to decline testing (Newson, 2008) .
Very little research has been made to explore the attitudes of women toward noninvasive prenatal diagnosis (Zamerowski et al., 2001; Kooj et al., 2009; Kelly and Farrimond, 2011) . The aim of this study was to assess whether pregnant women are interested in NIPD and what factors would influence their interest and expected uptake. We presented NIPD as being a diagnostic test with a level of accuracy similar to that of CVS and amniocentesis, because we expect that technical progress will allow this possibility in the near future, and the implications for NIPD testing are most significant if it has diagnostic capabilities.
METHODS
Pregnant women presenting for prenatal care to the outpatient Obstetrics Clinic or the Perinatal Diagnostic Center (PDC) of Lucile Packard Children's Hospital, Palo Alto, California were identified for possible enrollment. Enrollment was only offered to women who were at least 24 weeks' gestation, over 18 years old, and spoke and read English. Women were approached in the waiting room and asked to complete a written survey before or after their clinic visit. English proficiency was assessed by the primary investigator (RT) prior to survey administration.
Two versions of a written survey were developed by the investigators (available by request to corresponding author). Survey questions and the related introductory material were identical with the exception of the introductory sections describing NIPD -one version contained a brief NIPD description and the other had a longer, slightly more comprehensive description of the testing (see Appendix I). In consideration of potential informed consent concerns surrounding NIPD, we chose to create the different descriptions to ascertain whether the amount and level of detail given would influence the hypothetical uptake of this testing. The language and ordering of information was kept as similar as possible between the two survey versions. Each woman was asked to complete only one version of the survey and was not told that there were multiple versions. The two survey types were identical in outward appearance and versions were alternated between each prospective participant.
Both versions of the survey began with an introductory section that described the background risk of having a baby with a birth defect and gave a brief overview of currently available invasive testing options, their associated risk of miscarriage and the options that are available to a woman if a chromosome abnormality is diagnosed prenatally.
Noninvasive prenatal diagnosis was then introduced as an alternative to invasive testing that might become available in the near future. NIPD testing was described as being available earlier than invasive testing (potentially starting as early as 7-10 weeks) and having a similar level of accuracy as CVS and amniocentesis. NIPD was described as being completely safe for the fetus with no risk of miscarriage. The long version also had a more detailed discussion of NIPD that explained that the earlier timeframe would allow a woman more time to consider her options and allow more privacy in doing so, but also could identify some affected pregnancies that would have naturally ended in miscarriage, and may require an invasive test to clarify the results. The long version had a more extensive discussion of why a person might want (or not want) the information supplied by prenatal diagnostic testing including the statement 'Some reasons why people might want this information include: it would help them prepare for the birth of a child with a disability; the test results would decrease their anxiety; or they may consider terminating a pregnancy if a birth defect was found. Other people may not want this information because it would not impact how they would proceed with the pregnancy.'
After the description of NIPD was given, both versions of the survey had identical questions addressing four areas: (1) demographics (11 questions) including questions addressing previous uptake of prenatal screening and diagnosis in the current or past pregnancies, (2) 11 questions, primarily in Likert format, about the woman's level of interest in NIPD and the various factors affecting her interest, (3) desire for genetic counseling before or after NIPD, and (4) likelihood to terminate an affected pregnancy. The survey took approximately 10 min to complete.
Data were analyzed using SPSS version 18. Five-point Likert scales were compressed to two or three categories to avoid small cell sizes. When inconsistencies were noted between the participant's response to their use of prenatal screening and diagnostic testing and the results of this testing, the answers were adjusted conservatively to show consistency. (Example: If the participant marked that they did not have prenatal screening and then indicated that they had a normal result to prenatal screening, the latter response was changed to 'I did not have prenatal screening.') Data were analyzed descriptively, and comparisons were made between the responses of women who read the short NIPD description versus the long NIPD description. Chi-square analysis was also used to determine the demographic factors affecting women's level of interest in NIPD technology.
The study methodology and survey were approved by the Stanford University Institutional Review Board.
RESULTS
We approached 141 women to complete the survey and 114 women returned completed surveys (80.9% response rate). Completion rates were slightly higher with the short description; 62 of 71 surveys with the short description and 52 of 70 surveys with the long description were returned. The vast majority of the surveys were completed by women at the outpatient obstetrics clinic (94.7%). Overall the cohort consisted of an ethnically diverse but highly educated population with a mean age of 31.6 AE 6.0 (range 19-47 years old) ( Table 1) . Eighty-one percent of women reported that they underwent prenatal screening in the current or a past pregnancy, and 21.4% of women had undergone an invasive diagnostic test (Table 2) .
Views toward NIPD are shown in Table 3 . The majority of women surveyed indicated that they would be interested in having NIPD testing if it were available (71.9%), although a significant minority expressed that they were ambivalent (22.7%) or uninterested (5.4%) in this type of testing. When asked to identify a single factor that was the most important for their decision about NIPD, women overwhelmingly indicated that the elimination of miscarriage risk was most important (75%), followed distantly by accuracy of the results (13%). More than 10% of women chose multiple answers to this question, and among these, the majority indicated the elimination of miscarriage risk as one of the factors that they chose.
Respondents indicated that they would want to have NIPD either in place of (~30%) or in addition to (~40%) current screening and diagnostic testing (Table 3) . Nearly 20% of respondents indicated that they would do whatever their doctor recommended regarding NIPD. The vast majority of women indicated interest in talking to a genetic counselor about NIPD (94.6%), but they were split about the ideal time when this should occur: before undergoing NIPD testing (32.4%), after results were received (47.8%), or both (14.4%).
Women's level of interest in NIPD testing did not significantly differ based on the amount of detail given in This data represents only women who underwent CVS or amniocentesis (n = 24). the description of NIPD at the start of the survey (74.1% interested with the brief description vs 69.2% interested with the detailed description; Χ 2 = 0.326; p = 0.568). However, women who indicated that they were less likely to terminate an affected pregnancy were more likely to be ambivalent or uninterested in NIPD (Χ 2 = 12.014; p = 0.002). Level of interest in NIPD was also significantly associated with older age (Χ 2 = 4.405; p = 0.036), higher education level (Χ 2 = 6.149; p = 0.013), and ethnicity (Χ 2 = 6.526; p = 0.011) such that women who reported their ethnicity as Caucasian or Asian were more likely to indicate interest in NIPD (Table 4) .
Women who received the detailed versus brief NIPD descriptions were significantly less likely to prefer NIPD as a replacement for currently available diagnostic tests (19.6% vs 40.7%; Χ 2 = 5.687; p = 0.017). There also seemed to be a trend that women who received the detailed description were more likely to want to follow-up a positive NIPD result with invasive testing for confirmation (41.2%) as compared with women who received the brief description (27.1%; Χ 2 = 2.422; p = 0.12). Women whose prenatal screening results indicated that they were at high risk for a chromosome abnormality or neural tube defect also appeared to be more likely to prefer NIPD over screening (7 of 10) compared with women whose prenatal screen showed a low or average risk (20 of 75), although the number of individuals in each category prohibited us from running a valid statistical analysis.
DISCUSSION
This study is one of the first to assess pregnant women's hypothetical views toward noninvasive prenatal diagnosis. Demographic factors and attitudes toward termination influenced women's level of interest in NIPD. Many women reported that they would follow their doctor's recommendations about NIPD, suggesting that informed consent for this testing is a critical issue.
Demographic factors that were associated with higher level of interest in NIPD included older age, higher education level, and Caucasian or Asian ethnicity. These findings are generally consistent with previous research on women's approaches to invasive prenatal testing. Uptake of prenatal diagnostic testing is higher in older women (Nakata et al., 2010; Van Landingham et al., 2011) and among those who are more educated (Saucier et al., 2005) . Uptake and attitudes toward invasive prenatal testing also differ between ethnicities (Kupperman et al., 1996; Learman et al., 2003; Saucier et al., 2005) , with Caucasian and Asian women being more likely to undergo invasive (Lumley et al., 2006) . Interestingly, self-reported religiosity was not significantly associated with interest in NIPD, although it was highly associated with a woman's likelihood to terminate an affected pregnancy (Χ 2 = 19.976; p = 0.001). This suggests that although religiosity may play a role in a woman's views about termination, disability, and the value of prenatal testing (White, 2009; Teman et al., 2010) it cannot be used to predict her attitudes toward NIPD.
Although there was a slight difference in interest level based on which NIPD description was given, this difference was not statistically significant. It is likely that our limited sample size would not have sufficient power to pick up small to moderate differences between the two survey versions. It is also possible that the level of detail or the specific areas that were lengthened, which mainly expanded on the pros and cons of NIPD testing, truly did not affect a woman's interest level. It is notable, however, that the women who read the longer description were less likely to consider NIPD to be a replacement for invasive prenatal diagnosis, but rather to think of it as a first step in their prenatal decision making.
When asked if they would prefer NIPD over current screening or diagnostic testing, 1 in 5 women reported that they would do whatever their doctor recommended. This indicates that for a significant portion of women a discussion with their healthcare provider, and the professional recommendation of their physician, would be crucial to their choice about the test. This discussion between the patient and healthcare provider surrounding NIPD has the potential to significantly affect a woman's views toward this type of testing. Considering the gravity of the information that can be obtained through NIPD and the potential difficult decisions that this testing could lead to, it is critical that women make a thoughtful and informed decision regarding this testing, which requires a comprehensive discussion about appropriate informed consent for NIPD testing.
Currently, the informed consent process for prenatal screening differs significantly from the consent procedure for invasive diagnostic testing (Benn and Chapman, 2010) . The consent process for invasive prenatal diagnostic testing is often quite rigorous; the patient generally meets with a healthcare professional to discuss the pros and cons of testing and the full implications of the information being obtained, and then again briefly discusses testing with the doctor who will perform the procedure before providing written consent. The consent process for prenatal screening is often much less thorough. Patient consent for maternal serum screening has historically been problematic (Benn and Chapman, 2009 ) with many women reporting unawareness in whether they underwent screening, and confusion regarding what the test is able to determine. Many women who undergo maternal serum screening seem to be passively involved in the decision to undergo the testing (Seror and Ville, 2009) or appear not to make an informed choice ( Van den Berg et al., 2005) . Although this situation is less than ideal, an opportunity for providing more information and guidance occurs if the woman is found to be at high risk. This two-step process allows women at high risk to receive thorough counseling without alarming low-risk women and saves time for the healthcare providers (Benn and Chapman, 2010) . When considering NIPD testing, it is unclear whether the consent process will follow the model of prenatal screening or invasive diagnostic testing.
Because NIPD would have no physical risks and would be logistically convenient, informed consent for NIPD may follow the model of prenatal screening, and several authors have expressed concern over this possibility (Wright and Chitty, 2009; Benn and Chapman, 2010; Deans and Newson, 2010) . Women undergo a multitude of blood tests during pregnancy and the similarity of this diagnostic test to other pregnancy blood draws might mask its implications and ramifications. NIPD testing could be performed virtually anywhere and could be ordered by a patient's obstetrician or primary care physician, eliminating the need for referral to a specialty center. Because of the noninvasive nature and the lack of miscarriage risk, obstetricians may be less likely to approach the consent process as rigorously for NIPD as they currently do for invasive diagnostic testing (Van den Heuvel et al., 2009) . While the elimination of physical risk removes one important aspect of the informed consent discussion for diagnostic testing, the information obtainable from this testing and the consequences of knowing this information, including the potential decisions that may arise if a fetus is diagnosed with aneuploidy, should also be a major focus of the consent process (Benn and Chapman, 2010; Deans and Newson, 2010) .
In our study, over a quarter of women were hesitant about NIPD testing. Considering this, we suggest that an in-depth discussion about the potential results and ramifications of this testing (such as an ultimate decision of whether to terminate the pregnancy) should occur before NIPD is undertaken. It is unclear who will be responsible for having this discussion with patients. The discussion could occur through the obstetrician or through referral to a genetic counselor. In our study, half of the respondents expressed interest in pretest genetic counseling and 94.6% were interested in discussing NIPD results with a genetic counselor at some point. Considering the limited number and distribution of genetic counselors nationwide, it will likely not be possible for counselors to be the sole, or even primary facilitators of informed consent for NIPD. Prenatal genetic counseling practice will need to develop approaches to work with obstetrical practices to ensure that appropriate information is provided to women to facilitate informed decisions at the point when NIPD becomes routinely available to all pregnant women.
Study limitations
This study was limited by its relatively small sample size, which although unusually diverse in ethnic background, had an over-representation of highly educated and older women. Nationwide, approximately 15% of pregnant women are 35 or older, compared with 33% in our sample (CDC National Vital Statistics System, 2008 data) . Because of the older age of this sample population, these women were at baseline higher risk to have a baby with a chromosomal abnormality than the general population, as indicated by the higher screen positive rate seen in our sample of 11% compared with the California average of 4.8% (California Dept of Public Health, 2009 PDC Manual) . Thirty-one percent of pregnant women have a college degree or higher nationwide, compared with 71% in our sample (CDC, 2008 data) . Because older women and highly educated women are more likely to demonstrate interest in prenatal diagnosis, this may have biased our results in favor of NIPD. Future studies with larger sample sizes and different populations would be useful to further determine women's attitudes toward NIPD. It is important to remember that women's current attitudes toward NIPD may not predict future uptake. Additional research into the best ways to provide informed choice to women regarding NIPD testing is also needed.
CONCLUSIONS
Pregnant women were generally interested in NIPD, although over a quarter reported that they were ambivalent or uninterested in this type of testing. Sufficient discussion between healthcare providers and patients about NIPD testing will likely be crucial to allow women to make an informed choice regarding NIPD. ACKNOWLEDGEMENT KEO and HTG were both funded in part by NHGRI Grant 5 P50 HG003389-05.
APPENDIX 1: NIPD DESCRIPTIONS

Brief NIPD description
Every pregnant woman has a chance to have a baby with a birth defect. There are some types of birth defects, called chromosome abnormalities, that we can learn about before the baby is born. Examples of chromosome abnormalities are Down syndrome and Trisomy 18 and there is no cure for these conditions. The risk for having a child with one of these conditions increases as a woman gets older, although it can happen to a woman of any age. The current tests that are available to diagnose chromosome abnormalities before birth are amniocentesis and chorionic villus sampling (CVS). These tests are very accurate but they are invasive tests and they have a small risk of causing a miscarriage (less than 1%). CVS can be carried out between 10 and 12 weeks of pregnancy and amniocentesis is available after 15 weeks of pregnancy.
If a chromosome abnormality is diagnosed prenatally, the available options are to continue the pregnancy and either keep the baby or give it up for adoption, or terminate the pregnancy. When deciding whether to have a diagnostic test for chromosome abnormalities, you should consider whether you would want to have this information about your developing baby and if you might do anything differently on the basis of the results.
A new test, called Non-Invasive Prenatal Diagnosis (NIPD), may soon be available that could diagnose chromosome abnormalities earlier in pregnancy (between 7-10 weeks). This test uses a sample of mom's blood and is completely safe for the unborn child. This test does NOT have a risk of miscarriage and we expect that it will have a similar level of accuracy as CVS and amniocentesis.
Detailed NIPD description
Every pregnant woman has a chance to have a baby with a birth defect. There are some types of birth defects, called chromosome abnormalities, that we can learn about before the baby is born. Examples of chromosome abnormalities are Down syndrome and Trisomy 18 and there is no cure for these conditions. The risk for having a child with one of these conditions increases as a woman gets older, although it can happen to a woman of any age. The current tests that are available to diagnose chromosome abnormalities before birth are amniocentesis and chorionic villus sampling (CVS). These tests are very accurate but they are invasive tests and they have a small risk of causing a miscarriage (less than 1%). CVS can be done between 10-12 weeks of pregnancy and amniocentesis is available after 15 weeks of pregnancy. If a chromosome abnormality is diagnosed prenatally, the available options are to continue the pregnancy and either keep the baby or give it up for adoption, or terminate the pregnancy. When deciding whether to have a diagnostic test for chromosome abnormalities, you should consider whether you would want to have this information about your developing baby. Some reasons why people might want this information include: it would help them prepare for the birth of a child with a disability; the test results would decrease their anxiety; or they may consider terminating a pregnancy if a birth defect was found. Other people may not want this information because it would not impact how they would proceed with the pregnancy.
A new test, called Non-Invasive Prenatal Diagnosis (NIPD), may soon be available that could diagnose chromosome abnormalities earlier in pregnancy. This test uses a sample of mom's blood and is completely safe for the unborn child. This test does NOT have a risk of miscarriage and we expect that it will have a similar level of accuracy as CVS and amniocentesis. Since NIPD testing can be performed very early in pregnancy (between 7-10 weeks), it could give a woman more time to consider her options regarding termination or continuation of the pregnancy. These test results would also be available to a woman before her pregnancy is physically visible to other people, allowing for a more private decision if she chose to terminate the pregnancy. It is important to realize that many pregnancies where the fetus has a chromosome abnormality will naturally end in a miscarriage and because this test is performed so early, it could identify a chromosome abnormality in a pregnancy that would naturally end in miscarriage. There is also some chance that NIPD testing could give an unclear result and an invasive test (CVS or amniocentesis) would be offered later in the pregnancy to clarify the results.
